1:21 PM · 8 April 2025

PBOC weakens yuan fixing in response to Trump's tariffs 🇨🇳

The Chinese yuan (USDCNH: +0.2%) is returning today to a historical low after the People’s Bank of China (PBOC) weakened the reference rate against the dollar to 7.2038 CNH. The exchange rate broke through the psychological 7.20 level for the first time since Donald Trump's November election and is now at its lowest point since September 2023.

The yuan’s devaluation is another step in the trade war between China and the United States, aimed at boosting the competitiveness of Chinese exports following a dramatic escalation in protectionism. Within a week, tariffs on Chinese goods entering the U.S. have exceeded 50%, while American-made products have been hit with 34% tariffs by China. The PBOC’s decision will certainly be a thorn in the side of the Republican administration, which—through the voices of Trump, Bessent, and Lutnick—has repeatedly accused U.S. trade partners of “currency manipulation” and deepening the American trade deficit.

On the other hand, a strategic devaluation brings its own set of risks:

  • Abandoning plans to stabilize the yuan may undermine investor confidence in Chinese assets, potentially triggering capital outflows and even greater volatility.

  • Further deterioration in relations between the world’s two largest economies, along with firm retaliation pledges from both sides, sets the stage for a significant slowdown in economic growth. In March, the OECD projected GDP losses of 0.7% for the U.S. and 0.1% for China within three years of implementing even modest 10% bilateral tariffs—highlighting just how high the stakes are, even with protectionism in such a limited form.

 

Source: xStation5

19 June 2026, 9:48 PM

Daily Summary: End of an Extremely Intense Week (19.06.2026)

19 June 2026, 8:51 PM

Three markets to watch next week: EURUSD, OIL, NASDAQ (19.06.2026)

19 June 2026, 4:14 PM

Market wrap: Limited volatility and a strong dollar

19 June 2026, 11:50 AM

Chart of the day: GBPCHF snaps back on retail sales recovery 🇬🇧 📈 (19.06.2026)

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.